EUVIMEDObjevte EUVIMED
Klinische Studie

Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents

Trevor N Johnson, Diansong Zhou, Khanh H Bui

Biopharmaceutics & Drug Disposition · 2014-09 · 35 (6) · 341-352

DOI: 10.1002/bdd.1899 ↗

At a glance

Klinische Studie in Biopharmaceutics & Drug Disposition, published online on 2014-08-06. Written by Trevor N Johnson and 2 co-authors. Institution: Simcyp Ltd, Sheffield, UK. Major MEDLINE topics: Models, Biological. Cited 78 times so far (Crossref); 26 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Quetiapine is an atypical antipsychotic drug with a high permeability, moderate solubility and defined as a Biopharmaceutics Classification System class ll compound. The pharmacokinetics (PK) of the quetiapine immediate‐release (IR) formulation has been studied in both adults and children, but the quetiapine extended‐release (XR) formulation has only been conducted in adults. The purpose of the current study was to use physiologically based pharmacokinetic modeling (PBPK) quantitatively to predict the PK of the XR formulation in children and adolescents. Using a ‘learn and confirm’ approach, PBPK models were developed employing in vitro ADME and physicochemical data, clinical PK data of quetiapine IR/XR in adults and clinical PK data of quetiapine IR in children. These models can predict well the effects of CYP3A4 inhibition and induction on the PK of quetiapine, the PK profile of quetiapine IR in children and adults, and the PK profile of quetiapine XR in adults. The AUC and C max ratios (children vs adults) for the different age groups were in reasonable agreement with the observed ratios. In addition, the PBPK model predicted that children and adolescents are likely to achieve a similar exposure following administration of either the XR formulation once daily or the IR formulation twice daily at similar total daily doses. The results from the study can help inform dosing regimens in pediatrics using the quetiapine XR formulation. Copyright © 2014 John Wiley & Sons, Ltd.

Subjects

MeSH terms (MEDLINE)

Models, BiologicalAdolescentAdultAntipsychotic AgentsCarbamazepineChildComputer SimulationCytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ADelayed-Action PreparationsDibenzothiazepinesDrug Administration ScheduleDrug InteractionsFemaleHumansKetoprofenMaleMiddle AgedQuetiapine FumarateTissue Distribution

Author keywords

PBPKextended-release formulationquetiapine

Substances

Antipsychotic AgentsDelayed-Action PreparationsDibenzothiazepinesQuetiapine FumarateCarbamazepineKetoprofenCYP2C9 protein, humanCytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3A

Authors and institutions

  • Simcyp Ltd, Sheffield, UK.

Cite

APA

Johnson, T. N., Zhou, D., & Bui, K. H. (2014). Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharmaceutics & Drug Disposition, 35(6), 341-352. https://doi.org/10.1002/bdd.1899

Vancouver

Johnson TN, Zhou D, Bui KH. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharmaceutics & Drug Disposition. 2014;35(6):341-352. doi:10.1002/bdd.1899

BibTeX
@article{Johnson2014,
  author = {Johnson, Trevor N and Zhou, Diansong and Bui, Khanh H},
  title = {Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2014},
  volume = {35},
  number = {6},
  pages = {341--352},
  doi = {10.1002/bdd.1899}
}
Start for free →